View Older Stories View More Recent Stories
-
Zuora Reports Second Quarter Fiscal 2024 Results
-
Juul plans to lay off 30% of workforce in cost-cut push - source
-
Analysis-With central banks' job half done, global inflation talk is shifting
-
Agenus (AGEN) Prioritizes Resources to Accelerate Registration and Commercialization of BOT/BAL Program in Multiple Cancers
-
Agenus Prioritizes Resources to Accelerate Registration and Commercialization of BOT/BAL Program in Multiple Cancers
-
Grab advances break-even timeline on boost from cost cuts, strong demand
-
Charles Schwab shares fall after announcing cost-cutting plan
-
Dick's Sporting shares slide as costs, inventory shrink slam annual profit outlook
-
Twist Bioscience Releases 2023 ESG Report and Quantifies Carbon Footprint of Manufacturing a Single Gene
-
Medtronic raises profit forecast as surgeries return to pre-pandemic levels
-
In AI push, Telenor hires Google Cloud's Amol Phadke as CTO
-
Charles Schwab to reduce headcount to bring down costs
-
Charles Schwab (SCHW) plans to cut headcount, professional services
-
Westpac flags higher expenses in quarterly update; shares drop
-
WeWork seeks to regain listing compliance with 1-for-40 reverse stock split
-
Express (EXPR) Plans 1-for-20 Reverse Stock Split, Provides Preliminary Q2 Results
-
Express, Inc. (EXPR) Provides Preliminary Second Quarter 2023 Results; Announces Further Strategic Actions and Goal to Deliver $200 Million in Annualized Savings by 2025
-
Univar Solutions and Climax Molybdenum Company Strengthen Lubricants Partnership with Exclusive Distribution Agreement into the Latin American Market
-
Fidelis CyberSecurity Files Lawsuit Against Partner One Capital Alleging Fraud, Bad Faith And Breach Of Contract
-
Pieris Pharma (PIRS) Announces Milestone Achievement for Boston Pharmaceuticals' Initiation of Phase 1/2 Study of BOS-342
-
Nanox Announces Second Quarter of 2023 Financial Results and Provides Business Update
-
Pieris Pharmaceuticals Announces Milestone Achievement for Boston Pharmaceuticals' Initiation of Phase 1/2 Study of BOS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecific
-
Alphabet's Verily plans cost cuts amid pressure on Other Bets unit - WSJ
-
Australia July jobs take a surprise fall as market loosens
-
Welcome to Memphis Launches Innovative Strategy to Support Hospitality Professionals
-
Univar Solutions Appointed Distributor for dsm-firmenich in Central America, Mexico, and the Caribbean
-
Panostaja's investment target Grano starts change negotiations
-
Morien Provides Status Update on the Donkin Mine
-
Loss-making Wheels Up to give 95% stake to lenders for $500 million
-
UK basic wage growth hits record, adding to Bank of England's worries
-
Suncor Energy Reports Second Quarter 2023 Results
-
Amazon's devices chief David Limp to retire after 13 years
-
Private jet firm Wheels Up considers options, including bankruptcy protection
-
SCYNEXIS Reports Second Quarter 2023 Financial Results and Provides Corporate Update
-
Venus Concept Announces Second Quarter of Fiscal Year 2023 Financial Results
-
Biocept Reports Second Quarter 2023 Financial Results
-
Barfresh Provides Second Quarter 2023 Results and Expects to Achieve Positive Adjusted EBITDA for the Fourth Quarter of 2023
-
Eiger BioPharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update
-
Venus Concept Announces Second Quarter of Fiscal Year 2023 Financial Results
-
VBI Vaccines Reports Second Quarter 2023 Financial Results
-
BioXcel cuts over 50% jobs as it pivots focus to retail market for agitation drug
-
New Covid vaccines are on the way as 'Eris' variant rises
-
A smooth 'last mile' to 2% inflation may not be a stretch for Fed
-
Sarcos Technology and Robotics (STRC) PT Lowered to $10 at Credit Suisse, 'Sales Cycles Continue to Lengthen'
-
Jet charter firm Wheels Up in talks with lenders amid cash crunch -WSJ
-
BiondVax Pharma (BVXV) Reports Q2, Provides Business Update
-
BiondVax Reports Second Quarter Financial Results and Provides Business Update
-
VIAVI ANNOUNCES FOURTH QUARTER AND YEAR ENDED FISCAL 2023 RESULTS
-
Iridex Reports Second Quarter 2023 Financial Results
-
Atreca Reports Second Quarter 2023 Financial Results and Announces Corporate Restructuring
